Hubei Daily Exclusive Interview: MiaoLingBio’s In-House Magnetic Bead Technology Advances Scientific

Hubei Daily Exclusive Interview: MiaoLingBio’s In-House Magnetic Bead Technology Advances Scientific Research

Recently, Wuhan MiaoLing Bio Technology Co., Ltd. was featured in a special report by Hubei Daily. As one of Hubei Province’s leading mainstream media outlets, Hubei Daily focused on cutting-edge advances in foundational tools for genetic research and took an in-depth look at MiaoLingBio’s achievements in plasmid library development, proprietary technologies, industrial applications, and global expansion.

The report provided a comprehensive overview of how MiaoLingBio is leveraging technological innovation to support scientific research and contribute to the life sciences industry.

A Leading 100,000+ In-Stock Plasmid Library

The report highlighted MiaoLingBio’s extensive in-stock plasmid library, which includes more than 100,000 plasmids and ranks among the largest of its kind in China. The collection covers a wide range of eukaryotic expression vectors, viral vectors, and other plasmid products, supporting applications ranging from basic research to preclinical development.

Inside the laboratory, automated extraction systems operate continuously around the clock. Each batch of plasmids undergoes rigorous multi-dimensional quality control, including electrophoresis analysis, concentration testing, and endotoxin testing, helping ensure consistent and reliable product quality.

At the same time, MiaoLingBio’s independently developed magnetic bead-based purification technology was a major focus of the report.

Breaking Through the Bottlenecks of Traditional Plasmid Purification

In genetic research and cell therapy, plasmids are essential experimental tools. Their extraction efficiency, purity, and endotoxin levels can directly affect downstream experiments and the pace of research and development.

For years, conventional plasmid extraction methods have faced persistent industry challenges, including relatively low processing efficiency, difficulties in controlling endotoxin levels, and high operating costs. These limitations can slow down research workflows and create additional barriers to the industrial development of emerging fields such as gene therapy.

To address these challenges, the MiaoLingBio R&D team spent nearly two years developing a new plasmid extraction reagent system and its supporting magnetic beads. The company also customized domestically manufactured automated extraction equipment, ultimately establishing a new magnetic bead-based plasmid purification workflow.

10× Higher Productivity with Stringent Endotoxin Control

According to Dr. Zheng, Head of R&D at MiaoLingBio, the core advantage of the technology lies in its dual improvement in productivity and product quality.

The extraction capacity increased from approximately 24 mg per day with conventional processes to 240 mg per day, representing a 10-fold increase in productivity.

At the same time, plasmid endotoxin levels are strictly controlled below 0.1 EU/μg, meeting the stringent requirements for transfection-grade plasmid DNA.

Even more importantly, the proprietary technology significantly reduces manufacturing costs. The final product cost is only approximately one-tenth that of imported reagent kits, enabling research teams to obtain high-quality plasmid products at substantially lower costs and delivering a practical combination of lower costs and higher efficiency.

As Dr. Zheng explained, “Almost every gene therapy drug begins its early-stage development with plasmids as an essential upstream tool.”

Supporting Gene Therapy, Cell Therapy, and Advanced Biomedical Research

Although MiaoLingBio does not directly manufacture finished therapeutic drugs, it serves as an important upstream technology provider for gene medicine development.

MiaoLing plasmids have been widely used in cutting-edge applications including gene therapy, cell therapy, and animal model development, providing stable and reliable starting materials for a wide range of scientific research projects.

Last year, China’s first domestically developed gene therapy product for hemophilia B was officially approved for commercial use. The therapy uses an adeno-associated virus (AAV) vector to deliver a coagulation factor gene into patients. Clinical-grade viral vectors of this type are manufactured using plasmids as critical upstream raw materials.

More Than a Decade of Plasmid Technology Development

Yin Chu, Founder of MiaoLingBio, stated that the breakthrough in magnetic bead-based purification technology represents more than a decade of accumulated expertise in the plasmid field. It is also an important example of the company’s commitment to supporting domestic substitution and enabling scientific innovation through independent technological development.

Looking ahead, MiaoLingBio will continue to increase its investment in R&D and focus on key areas including plasmid purification, vector construction, and viral vector packaging. The company plans to introduce more proprietary technologies and products while continuously expanding its in-stock plasmid library and improving its service infrastructure.

Through these efforts, MiaoLingBio aims to provide researchers worldwide with more efficient, reliable, and accessible genetic research tools while contributing to the high-quality development of China’s biopharmaceutical industry.

Rapid Growth and an Integrated Technology Platform

In 2025, MiaoLingBio generated annual revenue of RMB 34 million, maintaining a compound annual growth rate of approximately 30%–40%.

The company also operates a P2-level clean laboratory capable of providing high-standard lentiviral packaging services, further strengthening its integrated technology platform covering the full workflow from vector construction to viral vector production.

Expanding Global Access to Plasmid Products and Services

MiaoLingBio’s products and services are currently exported to multiple countries and regions, including the United States, Japan, India, Canada, and Vietnam.

To meet the continued growth of demand in the global scientific research market, the company has launched an expansion project for its large-scale in-stock plasmid library. The project is designed to increase the production capacity of the existing library of more than 100,000 plasmid types by 10-fold.

With greater scale, higher quality standards, and faster delivery, MiaoLingBio aims to provide stronger support for genetic research and biopharmaceutical innovation worldwide.

Bringing Plasmid Technology into Modern Agriculture

Beyond biomedical research, MiaoLingBio is also extending its plasmid and biotechnology expertise into modern agriculture.

The company has established a 600-mu ecological cultivation base in Ezhou, Hubei Province. Using plant virus-free tissue culture technology, the facility focuses on improving the quality of planting materials at the source and reducing the incidence of pests and diseases.

The cultivation process follows an ecological model without the use of pesticides or chemical fertilizers, creating an integrated approach that combines biotechnology with sustainable agriculture.

Recognized by Hubei Daily for Technological and Industry Contributions

The special report by Hubei Daily represents strong recognition of MiaoLingBio’s technological capabilities, industry value, and broader social contributions.

Looking ahead, MiaoLingBio will remain focused on technological innovation and product development. The company will continue expanding its in-stock plasmid library, improving plasmid purification technologies, and strengthening its end-to-end service capabilities.

By providing higher-quality, more efficient, and more convenient products and solutions, MiaoLingBio aims to reduce the operational burden on researchers, improve research efficiency, and continuously support innovation in genetic research and the high-quality development of the global biopharmaceutical industry.